ℹ️
🇬🇧
Search
Search for publications relevant for "advanced NSCLC"
advanced NSCLC
Publication
Class
Person
Publication
Programmes
publication
Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)
2022 |
First Faculty of Medicine
publication
Analysis of advancer NSCLC patients with prolonged progression-free survival after EGFR tyrosine kinase therapy
2011 |
First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
EGFR mutations in patients with advanced NSCLC
2012 |
Faculty of Medicine in Pilsen
publication
Treatment of locally advanced NSCLC in the context of current guidelines
2021 |
Publication without faculty affiliation
publication
Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy
2013 |
Faculty of Medicine in Pilsen
publication
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy
2016 |
Faculty of Medicine in Pilsen
publication
Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC
2019 |
First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Second Faculty of Medicine
publication
Conventional teatment of advanced NSCLC - retrospective study including 156 patients
2001 |
Faculty of Medicine in Hradec Králové
publication
Results of the evaluation of osimertinib in previously non-treated patients with EGFR-mutated advanced NSCLC: FLAURA study
2018 |
First Faculty of Medicine
publication
Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC
2023 |
Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Science
publication
Commenting on the study: efficacy and safety of maintenance treatment with pemetrexed in patients with advanced NSCLC nonskvamózním after induction therapy with pemetrexed plus cisplatin - comparison studies JMBD and PARAMOUNT
2014 |
Publication without faculty affiliation
publication
Current recommendations for the treatment of non -small-cell lung cancer with special focus to therapy of advanced NSCLC according to ESMO and NCCN guidelines and Blue Book
2015 |
Publication without faculty affiliation
publication
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
2009 |
Third Faculty of Medicine
publication
New options of expensive pneumo-oncological therapy for advanced non-small-cell lung carcinoma (NSCLC) in the first line based on morphological and molecular genetic diagnosis in the Czech Republic
2012 |
First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
publication
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
2008 |
Third Faculty of Medicine
publication
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer
2008 |
Third Faculty of Medicine
publication
Rare case of choroidal metastasis in ALK-positive NSCLC that responds to crizotinib
2019 |
First Faculty of Medicine
publication
New options for biologically targeted therapy of advanced non-small-cell lung cancer - sunitinib and sorasfenib
2010 |
Central Library of Charles University
publication
Follow-up of expensive pneumo-oncological treatment of advanced non-small cell lung cancer in the I. line of the TULUNG register in the Czech Republic
2013 |
First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
publication
First-line immunotherapy in NSCLC - what brought 2018
2018 |
Faculty of Medicine in Pilsen
publication
Biological treatment of lung cancer
2015 |
Publication without faculty affiliation
publication
Immunooncologic therapy of lung cancer. Present and perspectives
2020 |
Faculty of Medicine in Pilsen
publication
Cemiplimab: monotherapy and combination therapy of NSCLC - analysis of locally advanced disease
2023 |
First Faculty of Medicine
publication
Targeted treatment and immunotherapy of advanced non-small cell lung cancer
2022 |
First Faculty of Medicine
publication
Strategies for current NSCLC treatment
2020 |
Publication without faculty affiliation
publication
Treatment of lung cancer with targetable mutations - new drugs and indications
2023 |
First Faculty of Medicine
publication
Clinical dilemma of lung cancer treatment with anti-PD-1 therapy (nivolumab) in the discovery of rheumatological problems with joint swelling - case report
2020 |
First Faculty of Medicine
publication
Radiotherapy in non-small-cell lung cancer 2016
2016 |
Publication without faculty affiliation
publication
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice
2013 |
Faculty of Medicine in Pilsen
publication
Erlotinib in the treatment of advanced non-small cell lung cancer - present experience and results in the Czech Repuiblic
2018 |
First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine